Phase I designs that allow for uncertainty in the attribution of adverse events

是 否 +2 论坛币

k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群

赵安豆老师微信：zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

立即领取

感谢您参与论坛问题回答

经管之家送您两个论坛币！

+2 论坛币

SummaryIn determining dose limiting toxicities in phase I studies, it is necessary to attribute adverse events to being drug related or not. Such determination is subjective and may introduce bias. We develop methods for removing or at least diminishing the effect of this bias on the estimation of the maximum tolerated dose. The approach that we suggest takes into account the subjectivity in the attribution of adverse events by using model-based dose escalation designs. The results show that gains can be achieved in terms of accuracy by recovering information lost to biases. These biases are a result of ignoring the errors in toxicity attribution.

扫码加我 拉你入群

请注明：姓名-公司-职位

以便审核进群资格，未注明则拒绝

分享1 收藏0 回帖

关键词：Attribution uncertainty Uncertain certainty Certain events

http://onlinelibrary.wiley.com/doi/10.1111/rssc.12195/abstract

In determining dose limiting toxicities in phase I studies, it is necessary to attribute adverse events to being drug related or not.

Such determination is subjective and may introduce bias.

oliyiyi 发表于 2016-11-8 14:03
SummaryIn determining dose limiting toxicities in phase I studies, it is necessary to attribute adve ...

谢谢楼主分享的资料不错啊！

oliyiyi 发表于 2016-11-8 14:03
SummaryIn determining dose limiting toxicities in phase I studies, it is necessary to attribute adve ...

谢谢楼主分享的资料不错啊

谢谢分享